Cargando…
935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial
BACKGROUND: Lipohypertrophy is defined as excess fat deposition in abdominal defined as visceral adipose tissue (VAT) as well as in the dorsocervical region, breasts, trunk, and along with possible fat deposition in liver, muscle, myocardium and epicardium. Multiple factors have been described as co...
Autores principales: | Rahman, Farah, de Chantal, Marilyn, Mesquita, Pedro, Aberg, Judith A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776066/ http://dx.doi.org/10.1093/ofid/ofaa439.1121 |
Ejemplares similares
-
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
por: Rahman, Farah, et al.
Publicado: (2022) -
Tesamorelin: A hope for ART-induced lipodystrophy
por: Patel, Akash, et al.
Publicado: (2011) -
1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
por: McLaughlin, Taryn, et al.
Publicado: (2023) -
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
por: Bedimo, Roger
Publicado: (2011) -
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
por: Fourman, Lindsay T., et al.
Publicado: (2020)